Lung cancer in women: The differences in epidemiology, biology and treatment outcomes

Expert Review of Respiratory Medicine

Volumn 3, Issue 6, 2009, Pages 627-634

  Rivera, Maria Patricia ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Cancer of the lung in women; Dna repair; Estrogen receptor; Growth factor receptor; Human papillomavirus; Non small cell lung cancer; Sex differences in lung cancer; Small cell lung cancer

Indexed keywords

ANTINEOPLASTIC AGENT; CETUXIMAB; CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; CYTOCHROME P450 3A4; ERLOTINIB; ESTROGEN DERIVATIVE; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; GEFITINIB; GESTAGEN; GROWTH FACTOR RECEPTOR; K RAS PROTEIN; PLACEBO; POLYDEOXYRIBONUCLEOTIDE SYNTHASE; PROTEIN P53; SEX HORMONE;

CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER MORTALITY; CANCER RISK; CANCER SUSCEPTIBILITY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CIGARETTE SMOKING; CLINICAL TRIAL; DNA REPAIR; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; MOLECULAR BIOLOGY; PREVALENCE; REVIEW; SEX DIFFERENCE; SIDE EFFECT; TREATMENT OUTCOME; VIRUS INFECTION;

EID: 73549121297     PISSN: 17476348     EISSN: 17476356     Source Type: Journal    
DOI: 10.1586/ers.09.54     Document Type: Review

References (83)

1. Giovino GA. Epidemiology of tobacco use in the United States. Oncogene 21, 7326-7340 (2002).
2. Fiore MC, Novotney TE, Pierce JP et al. Trends in cigarette smoking in the United States: the changing influence of gender and race. JAMA 261, 49-55 (1989).
3. Centers for Disease Control and Prevention (CDC). Cigarette smoking among adults - United States 2007. Morb. Mortal. Wkly Rep. 57, 1221-1226 (2008).
4. Wallace JM, Vaughn MG, Bachman JG et al. Race/ethnicity, socioeconomic factors, and smoking among early adolescent girls in the United States. Drug Alcohol Depend. 104S, 42-49 (2009).
5. Jemal A, Murray T, Samuels A et al. Cancer Statistics 2003. CA Cancer J. Clin. 53, 5-26 (2003).
6. Fu JB, Kau Y, Severson RK et al. Impact of gender in lung cancer: analysis of the national SEER database. Chest 127, 768-777 (2005).
7. Jemal A, Seigel R, Ward E et al. Cancer Statistics 2009. CA Cancer J. Clin. 58, 71 (2009).
8. Fiore MC, Novotny TE, Pierce JP et al. Trends in cigarette smoking in the United States: the changing influence of gender and race. JAMA 261, 49-55 (1989).
9. Brownson RC, Chang JC, Davis JR. Gender and histologic type variations in smoking-related risk of lung cancer. Epidemiology 3, 61-64 (1992).
10. Risch HA, Howe GR, Jain M et al. Are female smokers at higher risk for lung cancer than male smokers? A case-control analysis by histologic type. Am. J. Epidemiol. 138, 281-293 (1993).
11. Zang EA, Wynder EL. Differences in lung cancer risk between men and women: examination of the evidence. J. Natl Cancer Inst. 88, 183-192 (1996).
12. Henschke CL, Yankelevitz DF, McCauley DI et al. Women's susceptibility to tobacco carcinogens and survival after diagnosis of lung cancer. JAMA 296, 180-184 (2006).
13. Prescott E, Osler M, Hein HO et al. Gender and smoking-related risk of lung cancer. Epidemiology 9, 79-83 (1998).
14. Hallpern MT, Gillespie BW, Warner KE. Patterns of absolute risk of lung cancer mortality in former smokers. J. Natl Cancer Inst. 85, 457-464 (1993).
15. Bach PB, Kattan MW, Thornquist MD et al. Variations in lung cancer risk among smokers. J. Natl Cancer Inst. 95, 470-478 (2003).
16. Bain C, Feskanich D, Speizer FE et al. Lung cancer rates in men and women with comparable histories of smoking. J. Natl Cancer Inst. 96, 826-834 (2004).
17. Chiba I, Takahashi T, Nau MM et al. Mutations in the p53 gene are frequent in primary resected NSCLC. Lung Cancer Study Group. Oncogene 10, 1603-1610 (1990).
18. Takahashi T, Takahashi T, Susuki H et al. The p53 gene is very frequently mutated in small cell lung cancer with a distinctive nucleotide substitution pattern. Oncogene 10, 1775-1778 (1991).
19. Mollerup S, Ryberg D, Hewer A. Sex differences in lung CYP1a1 expression and DNA adduct levels among lung cancer patients. Cancer Res. 59, 3317-3320 (1999).
20. Kure EH, Ryberg D, Hewer A et al. p53 mutations in lung tumours: relationship to gender and lung DNA adduct levels. Carcinogenesis 17, 2201-2205 (1996).
21. Tayooka S, Shimizu N, Gazdar A. The TP53 gene, tobacco exposure, and lung cancer. Hum. Mutat. 21, 229-239 (2003).
22. Rodenhuis S, Slebos RJ. The ras oncogene in human lung cancer. Am. Rev. Respir. Dis. 142, S27-S30 (1990).
23. Nelson HH, Christiani DC, Mark EJ et al. Implications and prognostic value of K-ras mutations for early stage lung cancer in women. J. Natl Cancer Inst. 91, 2032-2037 (1999).
24. Ahrendt SA, Decker PA, Alawi EA et al. Cigarette smoking is strongly associated with mutation of the K-ras gene in patients with primary adenocarcinoma of the lung. Cancer 92, 1525-1530 (2001).
25. Aaronson SA. Growth factors and cancer. Science 254, 1146-1153 (1991).
26. Siegfried JM, DeMichelle MA, Hunt JD et al. Expression of mRNA for gastrin-releasing peptide receptor by human bronchial epithelial cells; association with prolonged tobacco exposure and responsiveness to bombesin-like peptides. Am. J. Respir. Crit. Care Med. 156, 358-366 (1997).
27. Cuttita F, Carney DN, Mulshine J et al. Bombesin and gastrin releasing peptide increase tyrosine autocrine growth factors in human small-cell lung cancer. Nature 316, 823-826 (1985).
28. Leyton J, Garcia-Martin LJ, Tapia JA et al. Bombesin and gastrin releasing peptide increase tyrosine phosphorylation of focal adhesion kinas and paxillin in non-small cell lung cancer cells. Cancer Lett. 162, 87-95 (2001).
29. Shriver SP, Bourdeau HA, Gubish CT et al. Sex-specific expression of gastrin-releasing peptide receptor: relationship to smoking history and risk of lung cancer. J. Natl Cancer Inst. 92, 24-33 (2000).
30. Pellegrini C, Falleni M, Marchetti A et al. HER-2/Neu alterations in non-small-cell lung cancer: a comprehensive evaluation by real time RT-PCR, fluorescence in situ hybridization, and immunohistochemistry. Clin. Cancer Res. 9, 3645-3652 (2003).
31. Hirsch F, Veve R, Varella-Garcia M. Evaluation of Her2/neu expression in lung tumors by immunohistochemistry and fluorescence in situ hybridization. Proc. Am. Soc. Clin. Oncol. 19, 486a (2000).
32. Hsiegh CC, Chow KC, Fahn HJ et al. Prognostic significance of HER-2/neu expression in Stage I adenocarcinoma of lung. Ann. Thorac. Surg. 66, 1159-1163 (1998).
33. Nakachi K, Imai K, Hayashi S et al. Polymorphisms of the CYP1A1 and glutathione S-transferase genes associated with susceptibility to lung cancer in relation to cigarette dose in Japanese population. Cancer Res. 53, 2994-2999 (1993).
34. Gonzalez FJ, Crespi CL, Gelboin HV. DNA-expressed human cytochrome P450s: a new age of molecular toxicology and human risk assessment. Mutat. Res. 247, 113-117 (1991).
35. Spitz MR, Wei Q, Dong Q et al. Genetic susceptibility to lung cancer: the role of DNA damage and repair. Cancer Epidemiol. Biomarkers Prev. 12, 689-698 (2003).
36. Peluso M, Munnina A, Hoek G et al. DNA adducts and lung cancer risk: a prospective study. Cancer Res. 65, 8042-8048 (2005).
37. Gorlova OY, Weng SF, Zhang Y et al. DNA repair capacity and lung cancer risk in non-smokers. Cancer Epidemiol. Biomarkers Prev. 17, 1322-1328 (2008).
38. Wei Q, Cheng L, Amos CI et al. Repair of tobacco carcinogen-induced DNA adducts and lung cancer risk: a molecular epidemiological study. J. Natl Cancer Inst. 92, 1764-1772 (2000).
39. Cheng YW, Hsieh LL, Lin PP et al. Gender differences in DNA adduct levels among non-smoking lung cancer patients. Environm. Mol. Mutagen. 37, 304-310 (2001).
40. Lord RV, Brabender J, Gandara D. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin. Cancer Res. 8, 2286-2291 (2002).
41. Stabile LP, Gaither-Davis AL, Gubish CT et al. Human non-small cell lung tumors and cells derived from normal lung express both estrogen receptor α and β and show biological responses to estrogen. Cancer Res. 62, 2141-2150 (2002).
42. Yager JD, Liehr JG. Molecular mechanisms of estrogen carcinogenesis. Annu. Rev. Pharmacol. Toxicol. 36, 203-232 (1996).
43. Taioli E, Wynder EL. Endocrine factors and adenocarcinoma of the lung in women. J. Natl Cancer Inst. 86, 869-870 (1994).
44. Adami, HO, Persson I, Hoover R et al. Risk of cancer in women receiving hormone replacement therapy. Int. J. Cancer 44, 33-39 (1989).
45. Schabath MB, Wu X, Vassilopoulou SR et al. Hormone replacement therapy and lung cancer risk. A case control analysis. Clin. Cancer Res. 10, 113-123 (2004).
46. Chlebowski RT, Schwartz A, Wakelee H et al. Oestrogen plus progestin and lung cancer in postmenopausal women (Women's Health Initiative Trial): a post-hoc analysis of a randomized controlled trial. Lancet 374(9667), 1217-1218 (2009).
47. Chang YH, Huang HD, Shiau MY et al. The correlation of IL-6 and MCL-6 expression in human papilloma virus 16/18 infected lung cancer. Proc. Int. Assoc. Stud. Lung Cancer 41(Suppl. 2), S119 (2003).
48. Henning EM, Suo Z, Karlsen F et al. HPV positive bronchopulmonary carcinomas in women with previous high-grade cervical intraepithelial neoplasia (CIN III). Acta Oncol. 38, 639-647 (1999).
49. Cheng Y, Chiou H, Sheu G et al. The association of human papillomatous 16/18 infection with lung cancer among nonsmoking Taiwanese women. Cancer Res. 61, 2799-2803 (2001).
50. Gorgoulis VG, Zachartous P, Kotsinas A et al. Human papilloma virus (HPV) is possibly involved in laryngeal but not in lung carcinogenesis. Hum. Pathol. 30, 274-283 (1999).
51. Welt A, Hummel M, Niedobitek G et al. Human papilloma virus infection is not associated with bronchial carcinoma: evaluation by in situ hybridization and the polymerase chain reaction. J. Pathol. 181, 276-280 (1997).
52. Mannino DM, Aguayo SM, Petty TL et al. Low lung function and incident lung cancer in the United States; data from the First National Helath and Nutrition Examination Survery follow-up. Arch. Intern. Med. 163, 1475-1480 (2003).
53. Urdue MP, Gold L, Jarvholm B et al. Impaired lung function and lung cancer incidence in a cohort of Swedish construction workers. Thorax 62, 51-56 (2007).
54. Schwartz AG, Cote ML, Wenzlaff AS et al. Chronic obstructive lung diseases and risk of non-small cell lung cancer in women. J. Thorac. Oncol. 4, 291-299 (2009).
55. Osann KE, Anton-Culver H, Kurosaki T et al. Sex-differences in lung cancer risk associated with cigarette smoking. Int. J. Cancer 54, 44-48 (1993).
56. Greenberg R, Karson R, Baker J et al. Incidence of lung cancer by cell type: a population-based study in New Hampshire and Vermont. J. Natl Cancer Inst. 72, 599-603 (1984).
57. Thun MJ, Lally CA, Flannery JT et al. Cigarette smoking and changes in the histopathology of lung cancer. J. Natl Cancer Inst. 89, 1580-1586 (1997).
58. Stellman SD, Muscat JE, Thompson S et al. Risk of squamous cell carcinoma and adenocarcinoma to the lung in relation to lifetime filter cigarette smoking. Cancer 80, 382-388 (1997).
59. Barkley JE, Green MR. Bronchiolaveolar carcinoma. J. Clin. Oncol. 14, 2377-2386 (1996).
60. Albertine KH, Steiner RM, Radack DM et al. Analysis of cell type and radiographic presentation as predictors of the clinical course of patients with bronchioloalveolar cell carcinoma. Chest 113, 997-1006 (1998).
61. Schoenberg JB, Wilcox HB, Mason TJ et al. Variation in smoking-related lung cancer risk among New Jersey women. Am. J. Epidemiol. 130, 688-695 (1989).
62. Ramalingam S, Pawlish K, Gadgeel S. Lung cancer in young patients: analysis of a Surveillance, Epidemiology, and End Results Database. Am. J. Clin. Oncol. 16, 651-657 (1998).
63. Radzikowska E, Glaz P, Roszkowski K. Lung cancer in women: age, smoking, histology, performance status, stage, initial treatment and survival: population-based study of 20,561 cases. Ann. Oncol. 13, 1087-1093 (2002).
64. Asamura H, Goya T, Koshiishi Y et al. A Japanese Lung Cancer Registry study. Prognosis of 13,010 resected lung cancers. J. Thorac. Oncol. 3, 46-52 (2008).
65. Mitsudomi T, Tateishi M, Oka T et al. Longer survival after resection of non-small cell lung cancer in Japanese women. Ann. Thorac. Surg. 48, 639-642 (1989).
66. Minami H, Yoshimura M, Miyamoto Y et al. Lung cancer in women: sex-associated differences in survival of patients undergoing resection for lung cancer. Chest 118, 1603-1609 (2000).
67. Ferguson MK, Wang J, Hoffman PC. Sex-associated differences in survival of patients undergoing resection for lung cancer. Ann. Thorac. Surg. 69, 245-250 (2000).
68. Cerfolio RJ, Bryant A, Scott E et al. Women with pathologic stage I, II, and III non-small cell lung cancer have better survival than men. Chest 130, 1796-1802 (2006).
69. Movsas B, Bae K, Coyne J et al. The influence of gender, race, and/or marital status on survival in lung cancer patients: meta-analysis of radiation therapy oncology group (RTOG) trials. J. Thorac. Oncol. 3(11), Suppl. 4 (2008).
70. O'Connell J, Kris MG, Gralla RJ et al. Frequency and prognostic importance of pretreatment clinical characteristics in patients with advanced non-small cell lung cancer treated with combination chemotherapy. J. Clin. Oncol. 4, 1604-1614 (1986).
71. Albain KS, Crowley JJ, LeBlanc M et al. Determinants of improved outcome in small-cell lung cancer: an analysis of the 2,580-patient Southwest Oncology Group database. Am. J. Clin. Oncol. 8, 1563-1574 (1990).
72. Videtic GM, Reddy CA, Chao ST et al. Gender, race and survival. A study in non-small cell lung cancer brain metastases patients utilizing the Radiation Therapy Oncology Group recursive partitioning analysis classification. Int. J. Radiat. Oncol. Biol. Phys. 3, 1-7 (2009).
73. Pirker R, Pereira JR, Szczesna A et al. Cetuximab plus chemotherapy in patients with advanced non-small cell lung cancer (FLEX): an open-label randomized Phase III trial. Lancet 373, 1525-1531 (2009).
74. Fukuoka M, Yano S, Giaccone G. Multi-institutional randomized Phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J. Clin. Oncol. 21, 2237-2246 (2003).
75. Kris MG, Natale RB, Herbst RS. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small-cell lung cancer: a randomized trial. JAMA 290, 2149-2158 (2003).
76. Shepherd FA, Pereira JR, Ciuleanu T et al. Erlotinib in previously treated non-small cell lung cancer. N. Engl J. Med. 353, 123-132 (2005).
77. Lynch TJ, Bell DW, Sordella R et al. Activating mutation in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350, 2129-2139 (2004).
78. Guillermo PJ, Janne PA, Lee JC et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304, 1497-1500 (2004).
79. Rosell R, Moran T, Queralt C et al. Screening for epidermal growth factor receptor mutations in lung cancer. N. Engl. J. Med. 361, 958-967 (2009).
80. Sekine I, Sumi M, Ito Y et al. Gender differences in treatment outcomes in patients with stage III non-small cell lung cancer. Jpn. J. Clin. Oncol. 39(11), 707-712 (2009).
81. Albain KS, Crowley JJ, LeBlanc M et al. Determinants of improved outcome in small-cell lung cancer: an analysis of the 2,580-patient Southwest Oncology Group database. Am. J. Clin. Oncol. 8, 1563-1574 (1990).
82. Ganti AK, Sahmoun AE, Panwalkar AW, et al. Hormone replacement therapy is associated with decreased survival in women with lung cancer. J. Clin. Oncol. 24, 59-63 (2006).
83. Albain KS, Unger J, Gotay CC et al. Toxicity and survival by sex in patients with advanced non-small cell lung cancer (NSCLC) on modern Soutwest Oncology Group (SWOG) trials. [Abstract]. ASCO Proc. 25(18 Suppl.), 7549 (2007).